IL30440A - Pharmaceutical preparation for oral administration comprising an active drug and a resin - Google Patents

Pharmaceutical preparation for oral administration comprising an active drug and a resin

Info

Publication number: IL30440A
Authority: IL; Israel
Prior art keywords: drug; resin; dosage form; particles; tablet
Prior art date: 1967-08-18

Application number

IL30440A

Other languages

English (en)

Other versions

IL30440A0 (en

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1967-08-18

Filing date

1968-07-26

Publication date

1971-11-29

1968-07-26 Application filed by Abbott Lab filed Critical Abbott Lab

1968-09-26 Publication of IL30440A0 publication Critical patent/IL30440A0/xx

1971-11-29 Publication of IL30440A publication Critical patent/IL30440A/en

Links

229940079593 drug Drugs 0.000 title claims description 70
239000003814 drug Substances 0.000 title claims description 70
239000011347 resin Substances 0.000 title claims description 46
229920005989 resin Polymers 0.000 title claims description 46
239000000825 pharmaceutical preparation Substances 0.000 title description 2
239000002245 particle Substances 0.000 claims description 36
239000002552 dosage form Substances 0.000 claims description 27
210000002429 large intestine Anatomy 0.000 claims description 20
238000000576 coating method Methods 0.000 claims description 19
239000011248 coating agent Substances 0.000 claims description 18
238000000034 method Methods 0.000 claims description 11
YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 claims description 10
229960004142 erythromycin stearate Drugs 0.000 claims description 10
210000000813 small intestine Anatomy 0.000 claims description 9
238000007922 dissolution test Methods 0.000 claims description 7
230000000968 intestinal effect Effects 0.000 claims description 7
210000002784 stomach Anatomy 0.000 claims description 7
239000000725 suspension Substances 0.000 claims description 6
239000012530 fluid Substances 0.000 claims description 5
239000003826 tablet Substances 0.000 description 62
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 22
239000004480 active ingredient Substances 0.000 description 15
238000004090 dissolution Methods 0.000 description 14
229960003276 erythromycin Drugs 0.000 description 11
239000000243 solution Substances 0.000 description 11
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
230000036765 blood level Effects 0.000 description 6
235000011389 fruit/vegetable juice Nutrition 0.000 description 6
210000001035 gastrointestinal tract Anatomy 0.000 description 6
239000002775 capsule Substances 0.000 description 5
239000007884 disintegrant Substances 0.000 description 5
210000003608 fece Anatomy 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000006187 pill Substances 0.000 description 5
230000000699 topical effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
208000025865 Ulcer Diseases 0.000 description 3
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
244000045947 parasite Species 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
208000004881 Amebiasis Diseases 0.000 description 2
206010001980 Amoebiasis Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000029142 excretion Effects 0.000 description 2
230000002550 fecal effect Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000012085 test solution Substances 0.000 description 2
210000003812 trophozoite Anatomy 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
206010001986 Amoebic dysentery Diseases 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
206010022678 Intestinal infections Diseases 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
108010019160 Pancreatin Proteins 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical class CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000011609 ammonium molybdate Substances 0.000 description 1
APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
229940010552 ammonium molybdate Drugs 0.000 description 1
235000018660 ammonium molybdate Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960000691 diiodohydroxyquinoline Drugs 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
IHZDYHDJAVUIBH-UHFFFAOYSA-L disodium hydrogenarsenate Chemical compound [Na+].[Na+].O[As]([O-])([O-])=O IHZDYHDJAVUIBH-UHFFFAOYSA-L 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
UXZFQZANDVDGMM-UHFFFAOYSA-N iodoquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(I)C2=C1 UXZFQZANDVDGMM-UHFFFAOYSA-N 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229940111688 monobasic potassium phosphate Drugs 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229940055695 pancreatin Drugs 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000003108 parasitologic effect Effects 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
229940126702 topical medication Drugs 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000001043 yellow dye Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL30440A 1967-08-18 1968-07-26 Pharmaceutical preparation for oral administration comprising an active drug and a resin IL30440A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US66160067A	1967-08-18	1967-08-18

Publications (2)

Publication Number	Publication Date
IL30440A0 IL30440A0 (en)	1968-09-26
IL30440A true IL30440A (en)	1971-11-29

Family

ID=24654299

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL30440A IL30440A (en)	1967-08-18	1968-07-26	Pharmaceutical preparation for oral administration comprising an active drug and a resin

Country Status (7)

Country	Link
BR (1)	BR6801380D0 (fr)
DE (1)	DE1792283A1 (fr)
FR (2)	FR7750M (fr)
GB (1)	GB1219026A (fr)
IL (1)	IL30440A (fr)
OA (1)	OA02878A (fr)
PH (1)	PH10958A (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA825384B (en) *	1981-07-31	1983-05-25	Tillott J B Ltd	Orally administrable pharmaceutical compositions
FR2532177A1 (fr) *	1982-08-30	1984-03-02	Being Well Products Inc	Complement nutritionnel a zones de liberation determinees et son procede de fabrication
DE19732903A1 (de)	1997-07-30	1999-02-04	Falk Pharma Gmbh	Pellet-Formulierung zur Behandlung des Intestinaltraktes

1968
- 1968-07-23 PH PH9405A patent/PH10958A/en unknown
- 1968-07-26 IL IL30440A patent/IL30440A/en unknown
- 1968-08-02 GB GB37098/68A patent/GB1219026A/en not_active Expired
- 1968-08-07 FR FR162170A patent/FR7750M/fr not_active Expired
- 1968-08-07 FR FR1591602D patent/FR1591602A/fr not_active Expired
- 1968-08-09 BR BR201380/68A patent/BR6801380D0/pt unknown
- 1968-08-10 OA OA53353A patent/OA02878A/fr unknown
- 1968-08-14 DE DE19681792283 patent/DE1792283A1/de active Pending

Also Published As

Publication number	Publication date
DE1792283A1 (de)	1971-11-18
GB1219026A (en)	1971-01-13
IL30440A0 (en)	1968-09-26
BR6801380D0 (pt)	1973-02-08
FR7750M (fr)	1970-03-16
FR1591602A (fr)	1970-05-04
OA02878A (fr)	1970-12-15
PH10958A (en)	1977-10-13

Publication	Publication Date	Title
DK200300005U3 (da)	2003-04-25	Farmaceutiske pellets indeholdende tamsulosin
RU2201217C2 (ru)	2003-03-27	Таблетка с энтеросолюбильным покрытием и способ приготовления
JP2773959B2 (ja)	1998-07-09	大腸内放出性固形製剤
AU781058B2 (en)	2005-05-05	Delayed-action form of administration containing tramadol saccharinate
RU2095054C1 (ru)	1997-11-10	Твердая лекарственная форма для орального введения
US20240016753A1 (en)	2024-01-18	Pharmaceutical compositions
EP0194838A2 (fr)	1986-09-17	Formulation pharmaceutique à libération contrôlée
DK165670B (da)	1993-01-04	Laegemidler indeholdende 9-desoxo-11-desoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)oxy)-(9s)-erythromycin samt fremgangsmaade til fremstilling af saadanne laegemidler
JPH09500617A (ja)	1997-01-21	腸管の異常ｐＨ値の調整及び腸疾患の処置のために使用する組成物
RU2181043C2 (ru)	2002-04-10	Фармацевтическая композиция для орального введения с модифицированным высвобождением, содержащая 5-аск, и способ лечения кишечных заболеваний
WO2025081577A1 (fr)	2025-04-24	Formulation à enrobage entérique de prednisone et son procédé de préparation
US5234691A (en)	1993-08-10	Sustained-release prepararation of basic medical agent hydrochloride
DE69011618T2 (de)	1994-12-15	Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
US3784683A (en)	1974-01-08	Tablet preparation
RU98111765A (ru)	2000-05-20	Фармацевтическая композиция для орального введения с модифицированным высвобождением, содержащая 5-аск, и способ лечения кишечных заболеваний
JPH0354926B2 (fr)	1991-08-21
CN105267172B (zh)	2018-11-09	简易制备结肠炎和克罗恩病用高载药量缓释制剂的方法
CN108175849B (zh)	2021-08-27	聚普瑞锌口服制剂及在制备溃疡性结肠炎药物中的应用
US4863741A (en)	1989-09-05	Tablet composition for drug combinations
CH629960A5 (fr)	1982-05-28	Composition pharmaceutique.
EP0196002B1 (fr)	1991-07-03	Comprimés contenant une combinaison de médicaments
RU2790691C1 (ru)	2023-02-28	Способ получения фармацевтической композиции, содержащей нестероидный противовоспалительный препарат, ингибитор протонной помпы и антацид, фармацевтическая композиция, содержащая нестероидный противовоспалительный препарат, ингибитор протонной помпы и антацид, применение фармацевтической композиции
CZ205596A3 (en)	1996-10-16	Galenic form of 5-nitroimidazole derivatives and pharmaceutical composition containing thereof
RU2145847C1 (ru)	2000-02-27	Состав для капсул
DE102004027924A1 (de)	2005-12-29	Arzneiform, enthaltend den Wirkstoff Cholylsarcosin